Influence of Interferon and Radiation on Serotonin Content in Primary Carcinoid Cell Cultures

References

• Scherstén T, Ahlman H, Wängberg B, Granérus G, Grimelius L. Hyperthermic liver perfusion chemotherapy in the foregut carcinoid syndrome. Lancet 1991; 338: 568–9
   PubMedGoogle Scholar
• Moertel C G, Lefkopoulo M, Lipsitz S, Hahn R G, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil. or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Eng J Med 1992; 326: 519–23
   PubMed Web of Science ®Google Scholar
• Martin J K, Moertel C G, Adson M A, Schutt A J. Surgical treatment of functioning metastatic carcinoid tumors. Arch Surg 1983; 118: 537–42
   PubMedGoogle Scholar
• Saha S, Hoda S, Godfrey R, Sutherland C, Raybon K. Carcinoid tumors of the gastrointestinal tract: A 44-year experience. Southern Med J 1989; 82: 1501–5
   PubMedGoogle Scholar
• Coupe M, Levi S, Ellis M, et al. Therapy for symptoms in the carcinoid syndrome. Quart J Med 1989; 271: 1021–36
   Google Scholar
• Søreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumours. Surgery 1992; 111: 48–54
   PubMed Web of Science ®Google Scholar
• Marlink R G, Lokich J J, Robins J R, Clouse M E. Hepatic arterial embolization for metastatic hormone-secreting tumors. Cancer 1990; 65: 2227–32
   PubMed Web of Science ®Google Scholar
• McEntee G P, Nagorney D M, Kvols L K, Moertel C G, Grant C S. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091–6
   PubMed Web of Science ®Google Scholar
• Kvols L K. Therapeutic considerations for the malignant carcinoid syndrome. Acta Oncol 1989; 28: 433–8
   PubMed Web of Science ®Google Scholar
• Öberg K. Interferonbehandling vid neuroendokrina tumarer. (Interferon treatment of neuroendocrine tumours). Nord Med 1992; 107: 80–2, (in Norwegian)
   PubMedGoogle Scholar
• Hanssen L E, Schrumpf E, Jacobsen M B, et al. Extended experience with recombinant a-2b interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report. Acta Oncol 1991; 30: 523–8
   PubMed Web of Science ®Google Scholar
• Öberg K, Norheim I, Aim G. Treatment of malignant carcinoid tumors: A randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. Eur J Clin Oncol 1989; 25: 1475–9
   PubMedGoogle Scholar
• Oken M M, Kyle R A. Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma. Semin Oncol 1991; 18(Suppl 7)30–2
   PubMedGoogle Scholar
• Grahame-Smith D G. The carcinoid syndrome. Am J Cardiol 1968; 21: 376–86
   PubMed Web of Science ®Google Scholar
• Beauchamp R D, Coffey R J, Lyons R M, Perkett E A, Townsend C M, Jr, Moses H L. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res 1991; 51: 5253–60
   PubMed Web of Science ®Google Scholar
• Abell M R, Fayos J V, Lampe I. Pathology-radiation therapy conference: Metastatic carcinoid tumor. Univ Mich Med Cent J 1967; 33: 29–31
   PubMedGoogle Scholar
• Cooper R B, VanWay C W, Robinson W A. Carcinoid tumor of the thymus. Rocky Mt Med J 1979; 76: 238–40, 3d
   PubMedGoogle Scholar
• Goodner J T, Berg J W, Watson W L. The nonbenign nature of bronchial carcinoids and cylindromas. Cancer 1961; 14: 539–46
   PubMed Web of Science ®Google Scholar
• Harris A I, Montgomery A. Orbital carcinoid tumor. Am J Ophthalmol 1980; 90: 875–7
   PubMed Web of Science ®Google Scholar
• Rush J A, Waller R R, Campbell R J. Orbital carcinoid tumor metastatic from the colon. Am J Ophthalmol 1980; 89: 636–40
   PubMed Web of Science ®Google Scholar
• Salyer W R, Salyer D C, Eggleston J C. Carcinoid tumors of the thymus. Cancer 1976; 37: 958–73
   PubMed Web of Science ®Google Scholar
• Gaitan-Gaitan A, Rider W D, Bush R S. Carcinoid tumor-cure by irradiation. Int J Radiat Oncol Biol Phys 1975; 1: 9–13
   PubMedGoogle Scholar
• Keane T J, Rider W D, Harwood A R, Thomas G M, Cummings B J. Whole abdominal radiation in the management of metastatic gastrointestinal carcinoid tumor. Int J Radiat Oncol Biol Phys 1981; 7: 1519–21
   PubMed Web of Science ®Google Scholar
• Samlowski W E, Eyre H J, Sause W T. Evaluation of the response of unresectable carcinoid tumors to radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 301–5
   PubMed Web of Science ®Google Scholar
• Real F X, Krown S E, Nisce L Z, Oettgen H F. Unexpected toxicity from radiation therapy in two patients with Kaposi's sarcoma receiving interferon. J Biol Response Mod 1985; 4: 141–6
   PubMedGoogle Scholar
• Torrisi J, Berg C, Bonnem E, Dritschilo A. The combined use of interferon and radiotherapy in cancer management. Semin Oncol 1986; 3(Suppl 2)78–83
   Google Scholar
• Dritschilo A, Mossman K, Gray M, Sreevalsan T. Potentiation of radiation injury by interferon. Am J Clin Oncol 1982; 5: 79–82
   PubMed Web of Science ®Google Scholar
• Gould M N, Kakria R C, Olson S, Borden E C. Radiosensitiza-tion of human bronchogenic carcinoma cells by interferon beta. J Interferon Res 1984; 4: 123–8
   PubMedGoogle Scholar
• Sasa S, Blank C L, Wenke D C, Sczupak C A. Liquid-chromatographic determination of serotonin in serum and plasma. Clin Chem 1978; 24: 1509–14
   PubMed Web of Science ®Google Scholar
• Evers B M, Townsend C M, Jr, Upp J R, et al. Estblishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991; 101: 303–11
   PubMedGoogle Scholar
• Welander C E, Morgan T M, Homsley H D, Trotta P P, Spiegel R. Combined recombinant human interferon alpha2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 1985; 35: 721–9
   PubMed Web of Science ®Google Scholar
• Steel G G. The radiobiology of human tumour cells. Proceedings of St. Bartholomews Hospital 50th anniversary symposium. 1988; 61: 116–20, Br J Radiol Suppl 22
   Google Scholar
• Dvorak H F. Tumours: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Eng J Med 1986; 315: 1650–9
   PubMed Web of Science ®Google Scholar
• Denekamp J. Anti-vascular cancer therapy: Is it a dream or reality?. Eur J Surg 1991; 21–6, (Suppl 561)
   PubMedGoogle Scholar
• Drewinko B, Roper P R, Barlogie B. Patterns of cell survival following tretment with antitumor agents in vitro. Eur J Cancer 1979; 15: 93–9
   Google Scholar
• Von Hoff D D, Casper J, Bradley E, et al. Direct cloning of human neuroblastoma cells in soft agar culture. Cancer Res 1980; 40: 3591–9
   PubMedGoogle Scholar
• Bertoncello I, Bradley T R, Campbell J J, et al. Limitations of the clonal agar assay for the assessment of primary human ovarian tumour biopsies. Br J Cancer 1982; 45: 803–11
   PubMed Web of Science ®Google Scholar
• Good M, Lavin M, Chen P, Kidson C. Dependence on cloning method of survival of human melanoma cells after ultraviolet and ionizing radiation. Cancer Res 1978; 38: 4671–5
   PubMedGoogle Scholar
• Sutherland R M, Durand R E. Radiation response of multicell spheroids—an in vitro tumour model. Curr Top Radiat Res 1976; 11: 87–139
   PubMedGoogle Scholar
• Ortaldo J R, McCoy J L. Protective effect of interferon in mice previously exposed to lethal irradiation. Radiat Res 1980; 81: 262–6
   PubMedGoogle Scholar
• Mothersill C, Seymour C B, O'Brien A, Hennessy T. Proliferation of normal and malignant human epithelial cells post irradiation. Acta Oncol 1991; 30: 851–8
   PubMed Web of Science ®Google Scholar
• Wheeler K T, Nelson G B. Saturation of DNA repair by alkaline elution. Radiat Res 1991; 125: 227–9
   PubMed Web of Science ®Google Scholar
• Yasui H, Takai K, Yoshida R, Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indo-lamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci USA 1986; 83: 6622–6
   PubMed Web of Science ®Google Scholar
• Giacomini P, Fraioli R, Nistico P, et al. Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. Int J Cancer 1990; 46: 539–45
   PubMed Web of Science ®Google Scholar
• Immune regulation by characterized polyptides. UCLA symposia on molecular and cellular biology, G Goldstein, J F Bach, H Wigzell. New Series, 1987; 41
   Google Scholar
• Ortaldo J R, Mantovani A, Hobbs D, Rubinstein M, Pestka S, Herberman R B. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer 1983; 31: 285–9
   PubMed Web of Science ®Google Scholar
• Funa K, Aim G V, Rönnblom L, Öberg K. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin Exp Immunol 1983; 53: 716–24
   PubMed Web of Science ®Google Scholar
• Sekar V, Atmar V J, Arati R J, Krim M, Kuehn G D. Inhibition of ornithine decarboxylase in human fibroblast cells by type I and type II interferons. Biochem Biophys Res Commun 1983; 114: 950–4
   PubMed Web of Science ®Google Scholar
• Sodin A, Geetha B. Effect of cisplatin, lipopolysaccharide, muramyl dipeptide and recombinant interferon-gamma on murine macrophages in vitro. Nat Immun Cell Growth Regul 1989; 8: 108–16
   PubMedGoogle Scholar